USPTO serial 97842013
NUCLEIX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- JOHNSON, CLINTON J
- Law office
- TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NUCLEIX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Sheehan Anderson
JENNIFER SHEEHAN ANDERSON BRIDGE INTELLECTUAL PROPERTY SERVICES PLLC143 CADYCENTER, SUITE 209NORTHVILLE, MI 48167UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use | ACTIVE | — |
| 005 | Diagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer, precancerous conditions or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection or detection of or chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; diagnostic reagents for medical purposes | ACTIVE | — |
| 042 | Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays | ACTIVE | — |
| 044 | Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease and prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing cancer screening services; providing screening services for chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease; providing a website featuring information in the fields of the diagnosis and treatment of cancer and chronic obstructive pulmonary disease (COPD) or autoimmune disease or neurological disease | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Nucleix Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named NUCLEIX
- Prosecution event MAB2 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 20, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 20, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 4, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 13, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 7, 2023 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Apr 6, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 20, 2023 | NWAP | NEW APPLICATION ENTERED | — |